MA41314A - Régime posologique pour antagonistes de madcam - Google Patents

Régime posologique pour antagonistes de madcam

Info

Publication number
MA41314A
MA41314A MA041314A MA41314A MA41314A MA 41314 A MA41314 A MA 41314A MA 041314 A MA041314 A MA 041314A MA 41314 A MA41314 A MA 41314A MA 41314 A MA41314 A MA 41314A
Authority
MA
Morocco
Prior art keywords
madcam
antagonists
dosage regime
regime
dosage
Prior art date
Application number
MA041314A
Other languages
English (en)
Inventor
Alaa Ahmad
Anindita Banerjee
Fabio Cataldi
Robert A Clare
Gail M Comer
Mina Hassan-Zahraee
Karen Michelle Page
Vivekananda Pradhan
Mera Krishnan Tilley
Michael Steven Vincent
Schack David J Von
Weidong Zhang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55275128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41314(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA41314A publication Critical patent/MA41314A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
MA041314A 2015-01-09 2016-01-05 Régime posologique pour antagonistes de madcam MA41314A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101877P 2015-01-09 2015-01-09
US201562263197P 2015-12-04 2015-12-04
US201562263910P 2015-12-07 2015-12-07

Publications (1)

Publication Number Publication Date
MA41314A true MA41314A (fr) 2017-11-14

Family

ID=55275128

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041314A MA41314A (fr) 2015-01-09 2016-01-05 Régime posologique pour antagonistes de madcam

Country Status (16)

Country Link
US (2) US10851163B2 (fr)
EP (2) EP4112079A1 (fr)
JP (2) JP6779621B2 (fr)
KR (1) KR20170129104A (fr)
CN (3) CN114732899A (fr)
AU (2) AU2016205852B2 (fr)
BR (1) BR112017014793A2 (fr)
CA (1) CA2916283A1 (fr)
CL (1) CL2017001756A1 (fr)
EA (1) EA037288B1 (fr)
ES (1) ES2927958T3 (fr)
IL (1) IL253247B (fr)
MA (1) MA41314A (fr)
MX (1) MX2017009047A (fr)
SG (1) SG11201705604WA (fr)
WO (1) WO2016110806A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105572A1 (fr) * 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. Prévision du résultat de traitement avec un anticorps dirigé contre l'intégrine anti-α4β7
CA2916283A1 (fr) * 2015-01-09 2016-07-09 Pfizer Inc. Regime de dosage pour antagonistes de madcam
KR20200010354A (ko) * 2017-05-24 2020-01-30 팬디온 테라퓨틱스, 인코포레이티드 표적화된 면역관용
US20190169291A1 (en) 2017-07-14 2019-06-06 Pfizer Inc. Antibodies to MAdCAM
CN108118093A (zh) * 2018-03-06 2018-06-05 谢琳 Linc00426在制备骨肉瘤转移诊断产品中的用途
WO2021021924A1 (fr) * 2019-07-29 2021-02-04 Huang Cai Gu Formulation de médicaments par inhalation à base d'anticorps pour le traitement du cancer du poumon
CN113789328A (zh) * 2021-09-16 2021-12-14 中国人民解放军海军军医大学 lncRNA及其在免疫调控及免疫相关疾病诊治中的应用
CN114164211B (zh) * 2021-09-16 2024-02-27 中国人民解放军海军军医大学 lncRNA及其在肿瘤诊断、治疗和预后判断中的应用
CN116631510B (zh) * 2022-10-28 2024-01-12 中国人民解放军军事科学院军事医学研究院 一种用于鉴别诊断克罗恩病和溃疡性结肠炎的装置
WO2024110868A1 (fr) 2022-11-22 2024-05-30 Takeda Pharmaceutical Company Limited Régime posologique à base d'anticorps anti-madcam-1 pour traiter la stéatohépatite non alcoolique

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US7803904B2 (en) * 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US20070202097A1 (en) * 2003-03-10 2007-08-30 Krissansen Geoffrey W Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
JP2006249083A (ja) 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc 抗ｍ−ｃｓｆ抗体組成物
US20100119517A1 (en) 2005-07-08 2010-05-13 Pfizer Inc Use of Anti-MAdCAM Antibodies for the Treatment of Coeliac Disease and Tropical Sprue
PE20070374A1 (es) 2005-07-08 2007-05-12 Pfizer Ltd ANTICUERPOS ANTI-MAdCAM
WO2007007151A2 (fr) 2005-07-11 2007-01-18 Pfizer Limited Utilisation d'anticorps anti mad-cam dans le traitement de l'emphyseme
WO2007007159A2 (fr) 2005-07-11 2007-01-18 Pfizer Limited Anticorps anti-madcam servant a traiter des troubles uterins
WO2007007160A2 (fr) 2005-07-11 2007-01-18 Pfizer Limited Anticorps anti-madcam servant a traiter la fievre
WO2007007152A2 (fr) 2005-07-11 2007-01-18 Pfizer Limited Anticorps anti-madcam utilises pour le traitement de cancers metastatiques et du chlorome
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
DE102010013830A1 (de) * 2010-03-26 2011-09-29 Carl Zeiss Microlmaging Gmbh Mikroskop und Verfahren zur mikroskopischen Erfassung von Licht einer Probe
WO2014160753A1 (fr) * 2013-03-27 2014-10-02 Genentech, Inc. Utilisation de biomarqueurs pour évaluer le traitement de troubles gastro-intestinaux inflammatoires par des antagonistes de l'intégrine bêta7
CA2916283A1 (fr) 2015-01-09 2016-07-09 Pfizer Inc. Regime de dosage pour antagonistes de madcam

Also Published As

Publication number Publication date
WO2016110806A3 (fr) 2016-10-20
CN107427576A (zh) 2017-12-01
CL2017001756A1 (es) 2018-02-09
CA2916283A1 (fr) 2016-07-09
CN114732899A (zh) 2022-07-12
MX2017009047A (es) 2019-01-30
AU2016205852B2 (en) 2021-09-16
WO2016110806A2 (fr) 2016-07-14
JP2021011493A (ja) 2021-02-04
IL253247B (en) 2022-04-01
US20210324070A1 (en) 2021-10-21
IL253247A0 (en) 2017-08-31
AU2016205852A1 (en) 2017-07-20
AU2021250850A1 (en) 2021-11-04
BR112017014793A2 (pt) 2018-01-09
JP6779621B2 (ja) 2020-11-04
SG11201705604WA (en) 2017-08-30
KR20170129104A (ko) 2017-11-24
US10851163B2 (en) 2020-12-01
EA201791227A1 (ru) 2017-12-29
CN114377125A (zh) 2022-04-22
US20180273619A1 (en) 2018-09-27
JP2016128441A (ja) 2016-07-14
EP3242684B1 (fr) 2022-07-27
JP7142200B2 (ja) 2022-09-27
EA037288B1 (ru) 2021-03-04
ES2927958T3 (es) 2022-11-14
EP4112079A1 (fr) 2023-01-04
AU2021250850B2 (en) 2023-06-01
EP3242684A2 (fr) 2017-11-15
US11884726B2 (en) 2024-01-30

Similar Documents

Publication Publication Date Title
IL287437A (en) Flavociclib solid dosage forms
MA41314A (fr) Régime posologique pour antagonistes de madcam
ZA201803436B (en) Inhibitors of cxcr2
HK1245247A1 (zh) 溴結構域的抑制劑
SI3125893T1 (sl) Devterirani heterociklični zliti gama-karbolini kot antagonisti receptorjev 5-HT2A
DK3244948T3 (da) Bestemmelse af medikamentdosis
DK3272338T3 (da) Oral doseringsform for ketamin
HUP1400510A1 (hu) Gyógyászati TNFalfa ellenes antitest készítmény
DK3204398T3 (da) Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
DK3212637T3 (da) Dopamin-d3-receptorantagonistforbindelser
DK3334721T3 (da) Cgrp-receptorantagonister
HK1231482A1 (zh) 用於治療炎症的作用於多種前列腺素受體的拮抗劑
DK3310756T3 (da) Thromboxanreceptorantagonister
DK3215193T3 (da) Doseringsregime for pegyleret interferon
IL265662A (en) Pharmaceutical preparation of antagonist for 5-ht6
MA42309A (fr) Nouveau composé de tiacumicine pour régime posologique
DK3270923T3 (da) Terapeutisk middel til frontallapsdysfunktion
MC200163B1 (fr) Revêtement pour la protection des supports métalliques
TH1501006213A (th) รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์
UA33637S (uk) Елемент контейнера для відходів
UA32778S (uk) Обкладинка документа для виїзду за кордон
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม
FR3017893B1 (fr) Pierre tombale pour caveau
TH1501005346A (th) องค์ประกอบทางเภสัชกรรมของเอส-คีตามีน ไฮโดรคลอไรด์